Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

150%

3 of 2 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

5(62.5%)

Phase 3

2(25.0%)

Phase 1

1(12.5%)

8Total

Phase 2(5)

Phase 3(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05201638Phase 3Active Not Recruiting

Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

Role: lead

NCT05134441Phase 3Active Not Recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

Role: lead

NCT04379271Phase 2Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)

Role: lead

NCT05054140Phase 2Active Not Recruiting

Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis

Role: lead

NCT03846219Phase 2Active Not Recruiting

MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)

Role: lead

NCT03341962Phase 2Terminated

Phase 2 Dose-finding IMU-838 for Ulcerative Colitis

Role: lead

NCT05124795Phase 1Terminated

IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer

Role: lead

NCT04516915Phase 2Completed

IMU-838 and Oseltamivir in the Treatment of COVID-19

Role: collaborator

All 8 trials loaded